Recent deaths linked to Sarepta's gene therapies have profoundly affected families of Duchenne muscular dystrophy patients, who have embraced experimental treatments amid the disease's fatal trajectory. Advocates emphasize the importance of continued progress despite the risks, while critical voices highlight clinical trial data shortcomings and FDA’s controversial approvals. Sarepta's crisis has sparked debates over gene therapy safety, risk management, and regulatory oversight in rare genetic diseases.